title: Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking.
abstract: Antibody agonists targeting tumor necrosis factor (TNF) superfamily receptors, including CD40, are being tested therapeutically as anticancer agents. Studies in mice have shown that anti-CD40 monoclonal antibody (mAb) requires Fc-receptor (FcR) engagement to activate antitumor immunity. In contrast, we have reported that clinically active anti-human CD40 mAb CP-870,893 does not require FcR crosslinking, a finding with translational implications.
authors.affiliation: Abramson Family Cancer Research Institute; Perelman School of Medicine; University of Pennsylvania; Philadelphia, PA USA.
authors.forename: Lee P
authors.initials: LP
authors.lastname: Richman
authors.affiliation: Abramson Family Cancer Research Institute; Perelman School of Medicine; University of Pennsylvania; Philadelphia, PA USA.
authors.forename: Robert H
authors.initials: RH
authors.lastname: Vonderheide
keywords: CD40; Fc receptor; immunotherapy; tumor immunity
references.citation: Cancer Immunol Res. 2014 Jan;2(1):19-26
references.pmid: 24416732
references.citation: J Immunol. 2011 Aug 15;187(4):1754-63
references.pmid: 21742972
references.citation: Cancer Immunol Immunother. 2013 May;62(5):941-8
references.pmid: 23543215
references.citation: J Clin Oncol. 2007 Mar 1;25(7):876-83
references.pmid: 17327609
references.citation: Clin Cancer Res. 2013 Mar 1;19(5):1035-43
references.pmid: 23460534
references.citation: Science. 2011 Aug 19;333(6045):1030-4
references.pmid: 21852502
references.citation: Immunology. 2001 Jan;102(1):39-43
references.pmid: 11168635
references.citation: Cancer Cell. 2011 Jan 18;19(1):101-13
references.pmid: 21251615
references.citation: Int Immunol. 1999 Jan;11(1):11-20
references.pmid: 10050669
references.citation: Science. 2011 Mar 25;331(6024):1612-6
references.pmid: 21436454